Revolution Medicines readies launch of experimental pancreatic cancer drug daraxonrasib as approval decision pending
read at Endpoints ↗Neutral
Revolution Medicines executives say they are preparing to launch daraxonrasib, an experimental therapy for metastatic pancreatic cancer.
The drug is currently awaiting regulatory decisions in the United States and Europe, and the company describes it as one of the most anticipated treatments in the sector.
The anticipated launch is expected to increase the company's 2026 operating expenses, reflecting higher manufacturing and commercial rollout costs.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Revolution Medicines preps for launching pancreatic cancer drug, ups 2026 expenses”
read at Endpoints ↗83 words · retrieved Aug 6
comments(0)
5-min edit window · permanent after that